– USA, CA – Dolby Laboratories, Inc. (NYSE: DLB) today announced the appointment of Emily Rollins to its Board of Directors and the Audit Committee of the Board, effective February 24, 2021.
“We are excited to welcome Emily to the Board of Directors,” said Board Chairman, Peter Gotcher. “Her financial expertise and extensive experience working with companies throughout the technology industry will enhance the strength of our Board.”
About Emily Rollins
Throughout her career at Deloitte & Touche LLP, Emily Rollins served in various positions since 1992, including as an Audit and Assurance Partner from 2006 until September 2020. At Deloitte, Ms. Rollins served technology and media companies and guided hundreds of clients through complex audit and reporting processes. Ms. Rollins also served in positions of increasing responsibility, including leadership roles in Deloitte’s US Technology, Media, and Telecommunications industry group, Audit Innovation and Transformation, and Diversity and Inclusion. She led firm-wide initiatives to recruit, develop, and retain women and diverse professionals as well as transform and modernize Deloitte’s audit platform.
About Dolby Laboratories
Dolby Laboratories is based in San Francisco, California with offices around the globe. From movies and TV shows to apps, music, sports, and gaming, Dolby transforms the science of sight and sound into spectacular experiences for billions of people worldwide. We partner with artists, storytellers, developers, and businesses to revolutionize entertainment and communications with Dolby Atmos, Dolby Vision, Dolby Cinema, and Dolby.io.
For more information: https://www.dolby.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.